[Clinical experience with mezlocillin in infections of mouth and jaw (author's transl)].
The effectiveness and tolerance of the new semisynthetic acylureidopenicillin 6-[(R)-2-[3-methylsulfonyl-2-oxo-imidazolidine-1-carboxamido]-2-phenyl-acetamido]-penicillanic acid sodium salt (mezlocillin, Baypen) were investigated in 10 patients with bone and soft tissue infections of the mouth and jaw. The antibiotic was given in doses of 2 to 10 g/d. Indications for treatment were osteomyelitis of the jaw and/or phlegmon of the floor of the mouth and abscesses of the soft palate. 9 out of 10 infections could be cured. Due to the short treatment period one case was not assessable. In 6 patients 9 causative aerobic and anaerobic organisms were isolated which were eliminated. The clinical and laboratory control examinations did not reveal any adverse reactions.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000188:drug therapy*; D008297:Male; D008802:Mezlocillin; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy*; D010406:Penicillins / Q000008:administration & dosage / Q000627:therapeutic use*
D010406:Penicillins; D008802:Mezlocillin
Klinische Erfahrungen mit Mezlocillin bei Infektionen im Mund- und Kieferbereich.